| Dr Phillip Gabriel Bailey, MD | |
|
1515 Delhi St Ste 200, Dubuque, IA 52001-6320 | |
| (563) 557-7000 | |
| Not Available |
| Full Name | Dr Phillip Gabriel Bailey |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 11 Years |
| Location | 1515 Delhi St Ste 200, Dubuque, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063858553 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Finley Hospital | Dubuque, IA | Hospital |
| Jackson County Regional Health Center | Maquoketa, IA | Hospital |
| Midwest Medical Center | Galena, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dubuque Surgery Pc | 8628969714 | 3 |
News Archive
GlaxoSmithKline has issued the following response to an article in the New England Journal of Medicine (NEJM) on Avandia (rosiglitazone maleate), a widely used and highly effective treatment for type 2 diabetes.
The U.S. Justice Department is suing Blue Cross Blue Shield of Michigan and alleging that it violated antitrust laws by forcing hospitals to charge higher prices to rival insurers.
Regulus Therapeutics Inc. and sanofi-aventis announced today that they have entered into a global, strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance represents the largest microRNA partnership formed to date, valued at potentially over $750 million, and includes a $25 million upfront fee, a $10 million future equity investment subject to mutual agreement on company valuation, and annual research support for three years with the option to extend two additional years.
The National Institutes of Health today announced a new initiative aimed at speeding innovation, development and commercialization of COVID-19 testing technologies, a pivotal component needed to return to normal during this unprecedented global pandemic.
› Verified 9 days ago
| Entity Name | Jackson County Public Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689705949 PECOS PAC ID: 1254248958 Enrollment ID: O20040120000117 |
News Archive
GlaxoSmithKline has issued the following response to an article in the New England Journal of Medicine (NEJM) on Avandia (rosiglitazone maleate), a widely used and highly effective treatment for type 2 diabetes.
The U.S. Justice Department is suing Blue Cross Blue Shield of Michigan and alleging that it violated antitrust laws by forcing hospitals to charge higher prices to rival insurers.
Regulus Therapeutics Inc. and sanofi-aventis announced today that they have entered into a global, strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance represents the largest microRNA partnership formed to date, valued at potentially over $750 million, and includes a $25 million upfront fee, a $10 million future equity investment subject to mutual agreement on company valuation, and annual research support for three years with the option to extend two additional years.
The National Institutes of Health today announced a new initiative aimed at speeding innovation, development and commercialization of COVID-19 testing technologies, a pivotal component needed to return to normal during this unprecedented global pandemic.
› Verified 9 days ago
| Entity Name | Dubuque Surgery Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508877283 PECOS PAC ID: 8628969714 Enrollment ID: O20040319001502 |
News Archive
GlaxoSmithKline has issued the following response to an article in the New England Journal of Medicine (NEJM) on Avandia (rosiglitazone maleate), a widely used and highly effective treatment for type 2 diabetes.
The U.S. Justice Department is suing Blue Cross Blue Shield of Michigan and alleging that it violated antitrust laws by forcing hospitals to charge higher prices to rival insurers.
Regulus Therapeutics Inc. and sanofi-aventis announced today that they have entered into a global, strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance represents the largest microRNA partnership formed to date, valued at potentially over $750 million, and includes a $25 million upfront fee, a $10 million future equity investment subject to mutual agreement on company valuation, and annual research support for three years with the option to extend two additional years.
The National Institutes of Health today announced a new initiative aimed at speeding innovation, development and commercialization of COVID-19 testing technologies, a pivotal component needed to return to normal during this unprecedented global pandemic.
› Verified 9 days ago
| Entity Name | Jackson County Public Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1912960758 PECOS PAC ID: 1254248958 Enrollment ID: O20061104000661 |
News Archive
GlaxoSmithKline has issued the following response to an article in the New England Journal of Medicine (NEJM) on Avandia (rosiglitazone maleate), a widely used and highly effective treatment for type 2 diabetes.
The U.S. Justice Department is suing Blue Cross Blue Shield of Michigan and alleging that it violated antitrust laws by forcing hospitals to charge higher prices to rival insurers.
Regulus Therapeutics Inc. and sanofi-aventis announced today that they have entered into a global, strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance represents the largest microRNA partnership formed to date, valued at potentially over $750 million, and includes a $25 million upfront fee, a $10 million future equity investment subject to mutual agreement on company valuation, and annual research support for three years with the option to extend two additional years.
The National Institutes of Health today announced a new initiative aimed at speeding innovation, development and commercialization of COVID-19 testing technologies, a pivotal component needed to return to normal during this unprecedented global pandemic.
› Verified 9 days ago
| Entity Name | Jackson County Public Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1326002643 PECOS PAC ID: 1254248958 Enrollment ID: O20070103000149 |
News Archive
GlaxoSmithKline has issued the following response to an article in the New England Journal of Medicine (NEJM) on Avandia (rosiglitazone maleate), a widely used and highly effective treatment for type 2 diabetes.
The U.S. Justice Department is suing Blue Cross Blue Shield of Michigan and alleging that it violated antitrust laws by forcing hospitals to charge higher prices to rival insurers.
Regulus Therapeutics Inc. and sanofi-aventis announced today that they have entered into a global, strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance represents the largest microRNA partnership formed to date, valued at potentially over $750 million, and includes a $25 million upfront fee, a $10 million future equity investment subject to mutual agreement on company valuation, and annual research support for three years with the option to extend two additional years.
The National Institutes of Health today announced a new initiative aimed at speeding innovation, development and commercialization of COVID-19 testing technologies, a pivotal component needed to return to normal during this unprecedented global pandemic.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Phillip Gabriel Bailey, MD 1515 Delhi St Ste 200, Dubuque, IA 52001-6320 Ph: (563) 557-7000 | Dr Phillip Gabriel Bailey, MD 1515 Delhi St Ste 200, Dubuque, IA 52001-6320 Ph: (563) 557-7000 |
News Archive
GlaxoSmithKline has issued the following response to an article in the New England Journal of Medicine (NEJM) on Avandia (rosiglitazone maleate), a widely used and highly effective treatment for type 2 diabetes.
The U.S. Justice Department is suing Blue Cross Blue Shield of Michigan and alleging that it violated antitrust laws by forcing hospitals to charge higher prices to rival insurers.
Regulus Therapeutics Inc. and sanofi-aventis announced today that they have entered into a global, strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance represents the largest microRNA partnership formed to date, valued at potentially over $750 million, and includes a $25 million upfront fee, a $10 million future equity investment subject to mutual agreement on company valuation, and annual research support for three years with the option to extend two additional years.
The National Institutes of Health today announced a new initiative aimed at speeding innovation, development and commercialization of COVID-19 testing technologies, a pivotal component needed to return to normal during this unprecedented global pandemic.
› Verified 9 days ago
Joseph Bernard Fuller, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 1000 Langworthy St, Dubuque, IA 52001 Phone: 563-584-3450 Fax: 563-584-3171 | |
Christopher Omerza, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1000 Langworthy St, Dubuque, IA 52001 Phone: 563-584-3450 Fax: 563-584-3171 | |
Jacob Levi Wagner, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1515 Delhi St, Suite 200, Dubuque, IA 52001 Phone: 563-557-7000 Fax: 563-589-4050 | |
Dr. Garrett William Fleming, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1000 Langworthy St, Dubuque, IA 52001 Phone: 563-584-3450 Fax: 563-584-3171 | |
Roger Arthur Ott Jr., M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1000 Langworthy St, Dubuque, IA 52001 Phone: 563-584-3450 Fax: 563-584-3171 | |
Keith Alan Shaw, MD Surgery Medicare: Medicare Enrolled Practice Location: 1515 Delhi St, Ste 200, Dubuque, IA 52001 Phone: 563-557-7000 Fax: 563-589-4050 |